TheraNym Biologics invests $150 to 175 M for establishing manufacturing facility of mammalian cell culture bioreactors

Hyderabad-based TheraNym Biologics, a subsidiary of Aurobindo Pharma, has announced the addition to the existing CMO agreement with Merck Sharp & Dohme Singapore Trading, Singapore, (MSD) by execution of an additional product schedule.

This serves to further expand the existing CMO relationship initiated pursuant to the previously disclosed arrangement in May 2024.

Under this newly signed product schedule, TheraNym Biologics will construct greenfield project for commissioning a large scale mammalian drug substance manufacturing facility (Unit 2) housing a total of 60 KL bioreactor capacities.

Theranym will invest around $150 to 175 million for establishing manufacturing facility of mammalian cell culture bioreactors with an aggregate capacity of 60,000 litres, together with requisite downstream purification infrastructure to produce drug substance.